US$ 20.85
new glp-1 drugs in development Upcoming wave of hormone-based therapies set to change field of diabetes, obesity care Issue 42: GLP-1 RA Drug
Description
Insurers may be less incentivized to adopt coverage because they could attract a "more expensive" set of patients than competitors who don't participate, he said
Crohns Colitis 14 , 904914 (2020)

[DOI] [PubMed] [Google Scholar] 905.Gadde K.M., Allison D.B., Ryan D.H., Peterson C.A., Troupin B., Schwiers M.L

DPP4i, dipeptidyl peptidase-4 inhibitor
